Anti-IL-1β monoclonal antibody

Ilaris (canakinumab)

An approved treatment for Systemic Juvenile Idiopathic Arthritis.

FDA Approved (2013)by Novartis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

2013

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Canakinumab wherever you encounter it, plus the key facts at a glance.

Generic name: Canakinumab
Brand name: Ilaris
Development code: ACZ885
Drug class: Anti-IL-1β monoclonal antibody
Manufacturer: Novartis
How it's taken: Given as a subcutaneous injection (under the skin), 4mg/kg every 4 weeks.

A monthly injection that blocks IL-1β, the key inflammatory protein driving systemic JIA.

In pivotal trials, 84% of children achieved rapid symptom improvement within 15 days, and 42 of the 128 children taking steroids, about a third, stopped them entirely.

Follow Ilaris by email

We'll email you when Ilaris's FDA label changes, when the FDA acts on it, and when new trials for Systemic Juvenile Idiopathic Arthritis open. Unsubscribe anytime.

You'll get, for Systemic Juvenile Idiopathic Arthritis:

Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month

Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Canakinumab fits

First-line biologic option for systemic JIA alongside tocilizumab.

The IL-1 pathway is central to sJIA pathogenesis, making IL-1 inhibitors particularly effective.
Monthly dosing offers convenience over daily anakinra injections.
Choice between canakinumab and tocilizumab often depends on whether systemic features (favoring IL-1 blockade) or arthritis (potentially favoring IL-6 blockade) predominate.

How Canakinumab works

In systemic JIA, the immune system overproduces a protein called IL-1β that triggers intense, body-wide inflammation causing spiking fevers, salmon-pink rash, and joint destruction. Canakinumab is a laboratory-made antibody that circulates through the bloodstream and intercepts IL-1β molecules before they can activate immune cells.

When canakinumab binds to IL-1β, it neutralizes the protein and prevents it from reaching its receptors on cells. Without this signal, the inflammatory cascade that causes fevers, rash, and joint damage is interrupted. The effect is often dramatic, with many children experiencing resolution of systemic symptoms within days of the first dose.

Because canakinumab has a long half-life, it only needs to be injected once every 4 weeks. This makes it more convenient than anakinra (which requires daily injections) and allows for sustained IL-1β suppression throughout the dosing interval.

Side effects and safety

What patients report

Patients should not receive live vaccines while on treatment. Your doctor will test for tuberculosis (TB) before starting. Get medical help right away for signs of a serious allergic reaction, including a rare but severe reaction called DRESS that causes a serious skin rash. Macrophage activation syndrome (MAS), a life-threatening complication of systemic JIA, can still happen during treatment, and infections or disease flares can trigger it, so report fever or new symptoms to your child's doctor right away.

The label also notes that medicines that weaken the immune system may raise the risk of cancer.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Canakinumab

Given as a subcutaneous injection (under the skin), 4mg/kg every 4 weeks. The maximum single dose is 300mg. It comes in single-dose vials and is given by a healthcare provider. The ILARIS Companion support program can arrange for a nurse to give the injection at home.

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Ilaris

With private insurance, the drugmaker's copay card can lower what you pay for Ilaris. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. The charity fund for Systemic Juvenile Idiopathic Arthritis was not taking new applications on November 13, 2026. People on Medicare may still qualify for the drugmaker's free medicine program. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance

From the drugmaker

Ilaris (Canakinumab)

ILARIS Companion

Official program page Call 1-866-972-8315

Copay help
Eligible commercially insured patients pay no more than $30 per month, subject to an annual cap. Federal or state program patients not eligible.
For: private insurance · source
Insurance and case manager help
Benefits checks, prior authorization and appeals help, identifying support for uninsured and underinsured patients, delivery coordination, and home nurse injections.
The official page does not say who qualifies. Ask the program. · source
Other support
Free Trial Offer: one starter dose of Ilaris at no cost for new patients with urgent medical need, regardless of insurance. One-time use.
The official page does not say who qualifies. Ask the program. · source
Free medicine program
Novartis Patient Assistance Foundation provides Ilaris free to eligible patients who are uninsured or have government insurance and meet income limits.
For: no insurance, Medicare, Medicaid · source

Good to know: Free drug is through the separate Novartis Patient Assistance Foundation (1-800-277-2254); income limits apply. Program hours Mon-Fri 9 AM-6 PM ET.

Checked on the drugmaker's official pages on October 5, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Systemic Juvenile Idiopathic Arthritis

From a charity · The Assistance Fund
Juvenile Arthritis fund
Waitlist
Apply on the foundation’s page
Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 13, 2026.

Every program and charity fund for Systemic Juvenile Idiopathic Arthritis →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Canakinumab treatment timeline for Systemic Juvenile Idiopathic Arthritis

Tap how long you have been on Canakinumab to drop your pin on the road. Your answers stay on this device.

How long have you been on Canakinumab?

Which form do you take?

Has your child had blood work (CBC with differential, inflammatory markers, liver function) checked since starting canakinumab?

Anything you've noticed? Pick any that apply.

Answer the first 3 questions to see your plan.

Stage 1 of 5 · Start to 1 mo

Starting canakinumab

Your child is starting canakinumab (Ilaris) for systemic JIA. This is an IL-1 beta blocker given as a subcutaneous injection every 4 weeks. The dose is based on body weight (4mg/kg, up to 300mg). IL-1 is one of the key inflammatory proteins driving the fevers, rash, and joint inflammation in sJIA, so blocking it targets one of the main drivers of the disease. The 2026 ACR guidelines strongly recommend an IL-1 or IL-6 inhibitor as the first treatment for newly diagnosed sJIA and name no preferred choice. If your child was on corticosteroids before starting canakinumab, the goal will be to taper and eventually stop them. In clinical trials, canakinumab worked fast: in the main trial, 84% of children had at least 30% improvement and no fever by day 15, compared with 10% on placebo.

Coming up

After the first injection, your child's rheumatologist will check labs on a schedule they set to assess the initial response: CRP and ferritin (inflammatory markers), CBC (blood counts, especially neutrophils), and liver function. If the fevers and rash resolve quickly, that is an excellent early sign. Joint symptoms may take a bit longer to fully improve. If your child is on corticosteroids, the rheumatologist will decide when to begin a taper once the biologic is clearly working. The next canakinumab injection is at 4 weeks. Your child's rheumatologist will reassess at that point whether the response is adequate or if any adjustments are needed. Regarding vaccines: your child should not receive live vaccines (such as MMR, varicella, or live flu vaccine) while on canakinumab. Non-live vaccines (flu shot, COVID, DTaP) can usually still be given, so ask your child's doctor about timing. If possible, make sure your child is up to date on all age-appropriate vaccinations before starting the biologic. Before the first dose, the doctor checks your child for tuberculosis (TB), as the Ilaris label advises.

Get in touch with your rheumatology team if you notice

High fever with rapidly rising ferritin, dropping blood counts, or liver enzyme spikes (possible macrophage activation syndrome, or MAS, which is a medical emergency in sJIA)
Fever that does not resolve after the first injection and worsens, especially with new confusion, bleeding, or extreme fatigue (MAS can mimic a flare but requires different treatment)
Signs of serious infection: high fever with cough, difficulty breathing, or looking very ill (canakinumab suppresses part of the immune system)
Severe injection site reaction: large area of swelling, warmth, or spreading redness
New or worsening joint swelling in multiple joints despite starting treatment

Questions to take to your next visit

How will we know if canakinumab is working? What signs should I watch for?
When can we start tapering the steroids?
What do I do if my child develops a fever: is it a sJIA flare or could it be an infection? How do I tell the difference?
Are there vaccines my child should get or avoid while on canakinumab? (The label says to avoid live vaccines during treatment.)
What happens if my child gets sick between injections: should we delay the next injection?
How is the injection given: can we learn to do it at home?

See Systemic Juvenile Idiopathic Arthritis trials enrolling now

Every stage of Canakinumab treatment at a glance

Starting canakinumab Start to 1 mo

Early response 1 mo to 3 mo

Your child has had 1 to 3 monthly injections of canakinumab. The rheumatologist is evaluating the response: have the fevers stopped, has the rash resolved, are the joints improving, and have the inflammatory markers (CRP, ferritin) dropped toward normal? In the pivotal trials, the response rate was high and rapid. Among responders, 74% remained flare-free while continuing treatment. If your child is responding well, the fevers and rash should have resolved by now, and joint inflammation should be improving. The steroid taper should be underway if your child was on steroids. If your child has not responded as expected, the rheumatologist is considering whether to continue longer, switch to a different biologic (tocilizumab targets IL-6 instead of IL-1), or investigate whether the diagnosis needs reassessment.

For children responding well: the focus shifts to maintaining the response, completing the steroid taper, and monitoring for MAS (which can occur even when sJIA seems controlled). The goal is inactive disease: no fevers, no rash, no active joint inflammation, normal inflammatory markers. In the trials, some children reached inactive disease, and more did over longer follow-up. For children with partial response (fevers gone but joints still active, or vice versa): the rheumatologist may continue canakinumab while adding methotrexate for persistent arthritis, or consider switching to an IL-6 inhibitor if the arthritis component is dominant. For children not responding: switching from IL-1 blockade to IL-6 blockade (tocilizumab) is the standard next step. Some children respond better to one pathway than the other.

Response assessment 3 mo to 6 mo

By 3-6 months, your child's response to canakinumab is well-established. The rheumatologist is assessing whether your child has achieved inactive disease (the treatment target) or whether there is ongoing disease activity that needs to be addressed. Inactive disease means: no fever, no sJIA rash, no active arthritis, normal CRP, normal ferritin, and normal blood counts. If your child has reached this target, the plan is to continue canakinumab to maintain it. The steroid taper should be complete or nearly complete by now: in the clinical trials, a third of children were able to stop steroids entirely. Your rheumatologist may also order screening for sJIA-associated lung disease, as the 2026 ACR guidelines conditionally recommend routine screening.

For children in inactive disease, canakinumab usually continues with regular check-ups and labs. The 2026 ACR guidelines did not agree on how long a child should stay in inactive disease before tapering, and they favor a slow taper over stopping at once. Your child's rheumatologist will talk through the timing with you. Your child's growth, development, and school participation should all be improving. For children with ongoing disease activity: your rheumatologist will consider intensifying treatment. Options include adding methotrexate for persistent arthritis, switching to tocilizumab if the IL-1 pathway is not providing enough control, or in some cases trying a JAK inhibitor. For children who initially responded but then flared: some doctors may adjust the dose or timing, which goes beyond the label, before switching to another medicine.

Maintenance treatment 6 mo to 2 yr

Your child is in the maintenance phase of canakinumab treatment. If inactive disease has been achieved and maintained, the every-4-week injection is the ongoing routine. Monitoring visits with labs (CBC, CRP, ferritin, liver function) happen on a schedule your rheumatologist sets. The treatment goals during this phase are: keeping the disease inactive, supporting normal growth and development, maintaining normal school attendance and physical activity, and watching for long-term complications. Many children whose disease is well controlled are able to return to school, play, and everyday routines. The rheumatologist is also tracking whether your child might eventually be a candidate for tapering or stopping the biologic.

Once your child has stayed in inactive disease for a while with normal inflammatory markers, your rheumatologist may discuss reducing or stopping treatment. Experts have not agreed on how long to wait first. This is an individualized decision. Some children can successfully discontinue biologics and remain in remission, while others flare when treatment is reduced and need to restart. The longer the period of sustained inactive disease, the better the chance of successful discontinuation. If your child flares during a taper, the 2026 ACR guidelines suggest going back to the treatment plan that last worked. Your rheumatologist will also continue monitoring for sJIA-associated lung disease and MAS risk.

Long-term management 2 yr on

Your child has been on canakinumab for 2 years or more. At this point, the disease trajectory is well-established. Many children with sJIA who respond well to IL-1 blockade can achieve sustained remission, and some will transition to drug-free remission over time. Your child's management now includes the biologic therapy (if still ongoing), regular monitoring for disease activity and complications, and comprehensive pediatric care including growth monitoring, psychosocial support, and preparation for the transition to adult rheumatology care when appropriate.

The long-term outlook for sJIA has improved dramatically with the availability of targeted biologics. If your child has been in sustained remission, periodic attempts at tapering the biologic may be considered. If your child continues to need ongoing therapy, the plan is to maintain the current regimen with periodic reassessment. As your child approaches adolescence and young adulthood, transition planning to an adult rheumatologist becomes important. This should start years before the actual transfer of care. Long-term surveillance for sJIA complications (lung disease, amyloidosis, and growth effects) continues throughout.

This timeline shows typical patterns from the prescribing information, guidelines and published studies. Your own treatment may differ, and your rheumatology team is the source of truth for your plan. Last checked against the FDA label on November 8, 2026.

Sources

Clinical trial results

2 pivotal Phase 3 randomized controlled trials enrolled children with active systemic JIA. In the first trial, 84% of canakinumab-treated patients achieved JIA ACR30 response by day 15, compared to just 10% on placebo. Among responders, 74% remained flare-free versus 25% on placebo. Across both trials, 73% achieved JIA ACR50 and 31% reached inactive disease status. Corticosteroid doses dropped from 0.34 to 0.05mg/kg/day, with 33% of patients discontinuing steroids entirely.

Development history

Novartis developed canakinumab (ACZ885) as a highly specific IL-1β inhibitor. It was first approved in 2009 for cryopyrin-associated periodic syndromes (CAPS). Following successful trials demonstrating rapid resolution of systemic JIA symptoms, FDA approved canakinumab for sJIA in May 2013 in patients aged 2 and older. It remains one of the cornerstone biologic therapies for this condition.

Ask anything about Canakinumab

AI-powered answers from clinical trial databases, FDA reports, and medical literature

Start withor ask

Explore Systemic Juvenile Idiopathic Arthritis trials

Other Systemic Juvenile Idiopathic Arthritis treatments

Common questions about Canakinumab

▸What is Canakinumab (Ilaris)?

A monthly injection that blocks IL-1β, the key inflammatory protein driving systemic JIA. In pivotal trials, 84% of children achieved rapid symptom improvement within 15 days, and 42 of the 128 children taking steroids, about a third, stopped them entirely.

▸How does Canakinumab work?

▸What are the side effects of Canakinumab?

The most common side effects include injection site reactions (redness, pain, itching at the injection site), upper respiratory infections, nasopharyngitis, abdominal pain, headache, and nausea. Because canakinumab suppresses part of the immune system, there is an increased risk of infections. Neutropenia (low white blood cell counts) can occur and requires monitoring. Patients should not receive live vaccines while on treatment. Your doctor will test for tuberculosis (TB) before starting. Get medical help right away for signs of a serious allergic reaction, including a rare but severe reaction called DRESS that causes a serious skin rash. Macrophage activation syndrome (MAS), a life-threatening complication of systemic JIA, can still happen during treatment, and infections or disease flares can trigger it, so report fever or new symptoms to your child's doctor right away. The label also notes that medicines that weaken the immune system may raise the risk of cancer.

▸How is Canakinumab taken?

▸Is Canakinumab FDA approved?

Yes, Canakinumab (Ilaris) is FDA approved (2013) for the treatment of Systemic Juvenile Idiopathic Arthritis.

▸What is Ilaris used for in systemic JIA?

Ilaris (canakinumab) is an FDA-approved IL-1 beta blocker for systemic juvenile idiopathic arthritis in children aged 2 and older, approved for sJIA in May 2013. It targets the key inflammatory protein that causes fevers, rash, and joint destruction in sJIA. ^[2]

▸How quickly does canakinumab work for sJIA?

Canakinumab works rapidly. In the pivotal Phase 3 trials, 84% of children achieved a JIA ACR30 response within 15 days of the first dose compared with 10% on placebo, and 33% were able to stop corticosteroids entirely. ^[1]

▸How is Ilaris given for systemic JIA?

Ilaris (canakinumab) is given as a subcutaneous injection of 4mg/kg every 4 weeks, with a maximum single dose of 300mg. It comes in single-dose vials and is given by a healthcare provider, and the ILARIS Companion support program can arrange for a nurse to give the injection at home. Because canakinumab has a long half-life, once-monthly dosing keeps IL-1 beta suppressed throughout the dosing interval. ^[2]^[3]

▸What are the side effects of canakinumab?

The most common side effects of canakinumab (Ilaris) are injection site reactions, upper respiratory infections, nasopharyngitis, abdominal pain, headache, and nausea. Because it suppresses part of the immune system, infection risk is increased, neutropenia can occur and needs monitoring, live vaccines should be avoided, and your doctor will test for tuberculosis before starting. Macrophage activation syndrome can still happen during treatment, so report fever or new symptoms to your child's doctor right away. ^[2]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

New England Journal of Medicine · 2012. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. https://www.nejm.org/doi/full/10.1056/NEJMoa1205099
U.S. Food and Drug Administration. ILARIS (canakinumab) Label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e
Novartis Pharmaceuticals. Ilaris (canakinumab) for Systemic JIA. https://www.ilaris.com